Furthermore, comprehensive methylation analysis has unveiled aberrant methylation of CpG sites in syndecan 2 (SDC2) in tumor tissues of most CRC patients, demonstrating a huge potential for quantifying blood SDC2 methylation for early CRC detection [35]. This evidence concerns the gene SDC2 and colorectal carcinoma.